Doxazosin was recently withdrawn from this trial after an interim analysis showed the secondary end point of combined cardiovascular disease to be 25 ... (chlorthalidone) (12.5-25.0 mg/day) and ...

Davis et al. have published findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) demonstrating that chlorthalidone is superior to both amlodipine ...

Of the 13,523 patients randomized, 6,767 continued on hydrochlorothiazide and 6,756 were switched over to chlorthalidone at doses of 12.5 mg or 25 mg; 95% of both groups were on the lower of the ...